CRISPR reports Q3 revenue of $12.7 million
CRISPR Therapeutics said on Nov. 2, 2026 that third-quarter GAAP revenue was $12.7 million and the net loss was $111.4 million. Cash, cash equivalents, and marketable securities were $2,276.6 million at Sept. 30. The same release said Casgevy generated $99 million of third-quarter revenue, which Vertex books as product sales, and that more than 750 patients have started treatment.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email apostructura@gmail.com and we will fix it.